Risk of dementia and AD with prior exposure to NSAIDs in an elderly community-based cohort

Neurology

Volumn 72, Issue 22, 2009, Pages 1899-1905

  Breitner, J C S ^a,b,e   Haneuse, S J P A ^c   Walker, R ^c   Dublin, S ^c,d   Crane, P K ^b   Gray, S L ^d   Larson, E B ^c  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c CENTER FOR HEALTH STUDIES   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

^e VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E; DICLOFENAC; ETODOLAC; FENOPROFEN; FLURBIPROFEN; IBUPROFEN; INDOMETACIN; KETOPROFEN; KETOROLAC; MECLOFENAMIC ACID; MEFENAMIC ACID; NABUMETONE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OXAPROZIN; PIROXICAM; SULINDAC; TOLMETIN;

AGED; ALZHEIMER DISEASE; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DEMENTIA; DISEASE ASSOCIATION; DRUG EXPOSURE; DRUG USE; FEMALE; HUMAN; INCIDENT REPORT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK FACTOR;

EID: 66649131390     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e3181a18691     Document Type: Article

References (28)

1. Szekely CA, Town T, Zandi PP. NSAIDs for the chemo- prevention of Alzheimer's disease. Subcell Biochem 2007; 42:229-248.
2. Szekely CA, Green RC, Breitner JC, et al. No advantage of A beta 42-lowering NSAIDs for prevention of Alzheimer dementia in six pooled cohort studies. Neurology 2008;70: 2291-2298.
3. Arvanitakis Z, Grodstein F, Bienias JL, et al. Relation of NSAIDs to incident AD, change in cognitive function, and AD pathology. Neurology 2008;70:2219-2225.
4. Aisen PS, Schafer KA, Grundman M, et al. Effects of rofe- coxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. JAMA 2003;289: 2819-2826.
5. Thal LJ, Ferris SH, Kirby L, et al. A randomized, double- blind, study of rofecoxib in patients with mild cognitive impairment. Neuropsychopharmacology 2005;30:1204-1215.
6. in't Veld BA, Ruitenberg A, Hofman A, et al. Nonsteroidal antiinflammatorydrugs and the risk ofAlzheimer's disease. Engl J Med 2001;345:1515-1521.
7. Zandi PP, Anthony J, Hayden K, et al. Reduced incidence of AD with NSAID but not H2 receptor antagonists: theCache County Study. Neurology 2002;59:880-886.
8. AD APT Research Group. Naproxen and celecoxib do not prevent AD in early results from a randomized controlled.trial. Neurology 2007;68:1800-1808.
9. Kukull WA, Higdon R, Bowen JD, et al. Dementia and Alzheimer disease incidence: a prospective cohort study..Arch Neurol 2002;59:1737-1746.
10. Larson EB, Wang L, Bowen JD, et al. Exercise is associated with reduced risk for incident dementia among persons 65 years of age and older. Ann Intern Med 2006;144:73-81.
11. Hixson JE, Vernier DT. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with.haI. J Lipid Res 1990;31:545-548.
12. Emi M, Wu LL, Robertson MA, et al. Genotyping and sequence analysis of apolipoprotein E isoforms. Genomics1988;3:373-379.
13. Teng EL, Hasegawa K, Homma A, et al. The Cognitive Abilities Screening Instrument (CASI): a practical test for cross-cultural epidemiological studies ofdementia. Int Psy- chogeriatr 1994;6:45-58; discussion 62.
14. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders: DSM-IV. Washington, DC: American Psychiatric Association; 1994:886.
15. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS- ADRDA Work Group under the auspices of the Department of Health and Human Services Task force on Alzheimer's disease. Neurology 1984;34:939-944.
16. Drug Facts and Comparisons 2008, 62nd ed. St. Louis: Lippincott Williams & Wilkins; 2007.
17. Fleming TR, Harrington DP. Counting Processes and Survival Analysis. New York, NY: John Wiley & Sons; 1991.
18. Korn EL, Graubard BI, Midthune D. Time-to-event analysis of longitudinal follow-up of a survey: choice of the time-scale. Am J Epidemiol 1997;145:72-80.
19. McGeer PL, McGeer E, Rogers J, Sibley J. Anti- inflammatory drugs and Alzheimer disease. Lancet 1990;335:1037.
20. Rogers J, Kirby LC, Hempelman SR, et al. Clinical trial of indomethacin in Alzheimer's disease. Neurology 1993;43: 1609-1611.
21. Breitner JCS, Gau BA, Welsh KA, et al. Inverse association of anti-inflammatory treatments and Alzheimer's disease: initial results of a co-twin control study. Neurology 1994; 44:227-232.
22. Szekely C, Thorne J, Zandi P, et al. Nonsteroidal anti- inflammatory drugs for the prevention of Alzheimer's disease: a systematic review. Neuroepidemiology 2004: 159-169.
23. Vlad SC, Miller DR, Kowall NW, Felson DT. Protective effects of NSAIDs on the development of Alzheimer disease. Neurology 2008;70:1672-1677.
24. Ganguli M, Dodge HH, Chen P, et al. Ten-year incidence of dementia in a rural elderly US community population: the MoVIES Project. Neurology 2000;54:1109-1116.
25. Hernan MA, Alonso A, Logroscino G. Cigarette smoking and dementia: potential selection bias in the elderly. Epidemiology 2008;19:448-450.
26. Corder EH, Saunders AM, Strittmatter WJ, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 1993;261: 921-923.
27. Khachaturian KS, Corcoran C, Mayer LS, et al. Apoli- poprotein E epsilon4 count affects age at onset of Alzheimer disease, but not lifetime susceptibility: The Cache County Study. Arch Gen Psychiatry 2004;61:518-524.
28. Gedye A, Beattie BL, Tuokko H, et al. Severe head injury hastens age of onset of Alzheimer's disease. J Am Geriatr Soc 1989;37:970-973.